Work

Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma

Year: 2020

Type: article

Study design: Case Report

Abstract: Key Points We report a patient with hepatosplenic T-cell lymphoma (HSTL) and compare the disease to the derived xenograft model. Enhancer of zeste homolog 2 (EZH2) inhibitor treatment of an EZH2-mutant HSTL patient-derived xenograft model led to prolonged survival.

Source: Blood Advances

DOI: 10.1182/bloodadvances.2019001256

Authors: Yana Pikman, Amy Saur Conway, Amanda L. Robichaud, Samuel Kitara, Alanna J. Church, Alyssa L. Kennedy, Lewis B. Silverman, Amy L. Billett, David M. Weinstock, Marian H. Harris, Kimberly Stegmaier

Institutions: Dana-Farber Cancer Institute, Boston Children's Hospital, Broad Institute, Harvard University, Massachusetts Institute of Technology

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,800

Funders: St. Baldrick's Foundation, National Institutes of Health, National Cancer Institute

Awards: Targeting mitochondrial one carbon folate metabolism for novel T-cell acute lymphoblastic leukemia therapy, G6342997465, Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer

OpenAlex ID: W3013968074

FWCI: 0.657

Cites: 17

Cited by: 9

Related to: 10